

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 SEPTEMBER 2023

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

<u>Item</u>	<u>PBAC Advice</u>
Norethisterone with mestranol	<p>The sponsor requested the delisting of Norinyl[®] 1/28 (norethisterone with mestranol) from the Pharmaceutical Benefits Scheme (PBS).</p> <p>The PBAC noted the product was being discontinued by the sponsor and that there were available clinical alternatives. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Saquinavir	<p>The sponsor requested the delisting of Invirase[®] (saquinavir) from the PBS.</p> <p>The PBAC noted the low number of services in the last financial year and that there are multiple alternatives available on the PBS. The PBAC noted the sponsor intended to discontinue supply of the product in Australia. The PBAC advised the delisting of this drug would not result in an unmet clinical need.</p>

Brendon Wheatley
A/g Director
PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
23 August 2023